1. Introduction {#s0005}
===============

The pregnane X receptor (PXR), also known as NR1I2 (nuclear receptor subfamily 1, group I, member 2), SXR (steroid and xenobiotic sensing receptor), or PAR (pregnane activated receptor), regulates the expression of proteins involved in all three phases of drug metabolism and transport. PXR is a nuclear hormone receptor (NHR), one of a class of proteins characterized by a DNA-binding domain and activating function domains 1 and 2 (AF-1 and AF-2) that are relatively conserved in different species and, in PXR specifically, by a promiscuous ligand-binding domain (LBD)[@bib1], [@bib2], [@bib3], [@bib4]. NHRs bind to specific DNA sequences and bring the DNA molecule into the preferential steric conditions for transcription of target genes; in the case of PXR, these are predominantly genes involved in metabolizing xenobiotics. The LBD of PXR interacts with ligands to stabilize the protein (and recruit binding proteins, such as RXR, retinoic X receptor) and enable the recruitment of coactivators to the AF-2 region, resulting in further stabilization of the protein while in complex with DNA[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6]. PXR regulates the expression of phase I enzymes, including cytochrome P450 enzymes (CYPs) CYP3A4, CYP2B6, CYP2C9, and CYP2C19; phase II enzymes, including UDP-glucuronosyltransferase 1 family polypeptide A1 (UGT1A1), UGT1A2, and sulfotransferase 2 A (SULT2A); and phase III transporters, including ATP-binding cassette transporter ABCB1 (also known as MDR1 or P-gp), multiple organic anion transporters (OATs), and multidrug-resistance protein 3 (MRP3)[@bib2], [@bib3], [@bib4], [@bib7], [@bib8]. PXR is mainly expressed in the liver and the intestines[@bib9]. The recent identification of PXR as a potential therapeutic target in several diseases underscores the necessity of fully describing all variants of the receptor and their effect on physiologic and pathophysiologic processes[@bib10], [@bib11], [@bib12], [@bib13], [@bib14]. PXR has been implicated in the pathophysiology of bone disease[@bib11], inflammatory disorders[@bib13], [@bib14], and dyslipidemias[@bib10], in addition to its roles in hepatotoxicity and hepatic fibrosis[@bib15], [@bib16], [@bib17], [@bib18]. Because some PXR ligands are species-specific, a mouse model in which mouse PXR is replaced with human PXR (hPXR) enables examination of hPXR function *in vivo*[@bib19], [@bib20], [@bib21], [@bib22]; however, mouse models that are engineered to express only PXR variant 1 mRNA (*PXR1*) and protein fail to account for the multiple PXR transcripts. Therefore, a mouse model in which the entire *hPXR* gene is inserted into the mouse genome was created[@bib21], [@bib23].

Ligand activation of PXR results in the induction of target genes by a broad range of structurally dissimilar xenobiotics, leading to the metabolism of an even greater range of compounds than those that directly activate xenobiotic metabolism *via* activation of PXR ([Table 1](#t0005){ref-type="table"}[@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31]). Analgesics \[NSAIDs (nonsteroidalanti- inflammatory drugs) and non-NSAIDs\], protease inhibitors, antibacterials, anticonvulsants, glucocorticoids, and statins activate PXR ([Table 1](#t0005){ref-type="table"}). PXR is also activated by a structurally and functionally diverse set of ligands implicated in a range of disease states. PXR target genes display considerable interindividual variation in expression profile and enzymatic activity[@bib32], [@bib33], [@bib34]. Administration of xenobiotics to patients might cause adverse drug responses such as hepatotoxicity[@bib15], [@bib17], [@bib35], [@bib36]. Interindividual variability in drug response or nonresponse may result, in part, from variation in total PXR protein expression, single-nucleotide polymorphisms in coding or promoter regions of *PXR*, and variation in the relative expression of PXR isoforms[@bib9], [@bib32]. Interindividual variability in drug metabolism, therapeutic response, and the incidence and degree of dose-limiting toxicity may reflect, in part, variability in the expression levels of *PXR* transcript variants. There is considerable variability in *PXR* transcript expression in human liver and intestines; some patients express low levels of a common variant, whereas others express high levels of uncommon variants[@bib7], [@bib9], [@bib37], [@bib38], [@bib39]. These variants display altered transactivation activity towards target genes[@bib7], [@bib39]. In addition, PXR1 and PXR2 have separate transcription start sites[@bib40].

2. PXR and chemotherapeutic metabolism {#s0010}
======================================

Distinct from its less investigated direct role in cellular proliferation and senescence, PXR can play seemingly dual roles in the development of resistance to chemotherapeutic agents. For example, after treatment with a PXR agonist, an inactive anticancer prodrug is metabolized to a greater degree to an active metabolite which may confer the anticancer chemotherapeutic activity[@bib41]. Conversely, PXR activation may enhance the metabolism of the active forms of a drug into less active metabolites or excreted, with a resultant increase in resistance to chemotherapy[@bib28], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60]. The role of PXR in chemotherapeutic metabolism has been elegantly reviewed by Zhuo[@bib61].

Cyclophosphamide and ifosfamide are prodrugs that are converted by CYP3A4 and CYP2B6 to active 4-hydroxy metabolites[@bib41]. Indeed, the treatment with rifampicin and dexamethasone, both agonists of PXR, increases the metabolism of the prodrugs to their 4-hydroxy form to confer anticancer activity[@bib41]. Irinotecan is a prodrug that is metabolized by carboxylesterase to its active form SN38 and is further metabolized by UGT1A1 and, to a lesser extent, CYP3A4 to an inactive form, SN38 glucuronide (SN38G)[@bib57], [@bib58]. PXR protein overexpression, and activation by rifampicin and SN38 itself, results in increased metabolism to inactive SN38G[@bib42], [@bib43]. Tamoxifen is metabolized to 4-hydroxytamoxifen, a more active metabolite, by CYP2D6[@bib62]. Conversely, tamoxifen is metabolized by CYP3A4 to *N*-desmethyltamoxifen, a metabolite with very low activity[@bib63]. PXR protein overexpression and activation by rifampicin, SR12813, tamoxifen, and 4-hydroxytamoxifen lead to increased metabolism to *N*-desmethyltamoxifen and efflux which may result in increased resistance to chemotherapy[@bib48], [@bib49], [@bib60]. Paclitaxel is metabolized by CYP2C8 and CYP3A4 to inactive metabolites[@bib64], [@bib65]. *PXR* knockdown by small interfering RNA (siRNA) or short hairpin RNA (shRNA) results in increased sensitivity to therapy[@bib51], [@bib59], whereas the activation of PXR by rifampicin, paclitaxel, or SR12813 leads to increased metabolism and efflux of paclitaxel, resulting in increased resistance to chemotherapy[@bib44], [@bib50], [@bib51], [@bib59]. Doxorubicin is metabolized directly by the Cyp3a family or by carbonyl reductases to doxorubicinol and is further metabolized by Cyp3a enzymes to inactive aglycone metabolites[@bib66]. Additionally, transcriptional activation of PXR by either overexpressing a constitutively active PXR protein or binding of rifampicin to the wild-type hPXR results in decreased sensitivity to doxorubicin[@bib39], [@bib67]. Vinblastine is metabolized by CYP3A4 and CYP3A5 to inactive metabolites[@bib68]. Pretreatment with a PXR agonist decreases the sensitivity of cancer cells to vinblastine treatment, whereas siRNA knockdown of *PXR* increases their sensitivity to vinblastine[@bib51], [@bib56]. Together, these results clearly demonstrate the roles of PXR in regulating the efficacy of chemotherapeutic agents.

3. Structural, functional, and expression characteristics of *PXR* transcript variants {#s0015}
======================================================================================

The *PXR* gene located on chromosome 3 encodes multiple transcript variants, resulting in structurally and functionally distinct proteins[@bib3], [@bib7], [@bib37], [@bib38], [@bib39], [@bib69], [@bib70]. The identification of 9 splicing and transcript variants of *PXR* in human livers has led to the postulation that these variants, which may have different transactivation activity, contribute to interindividual variability in the expression of drug-metabolizing enzymes and efflux transporters, such as CYP3A4 and P-gp[@bib69]. Recent work has focused on four of these mRNA transcript variants. The *hPXR* gene (NC_000003.12, [Fig. 1](#f0005){ref-type="fig"}) is located on chromosome 3q12-q13.3 and consists of approximately 38,000 base pairs[@bib69]. *PXR1* mRNA possesses the noncoding exon 1a of the *hPXR* gene and is transcribed into an mRNA of approximately 4400 nucleotides (NM_003889), which is then translated into a protein of 434 amino acids using a CTG start codon in exon 2 (NP_003880). *PXR3* mRNA, a splicing variant of *PXR1*, originates from exon 1a of the *hPXR* gene, which contains a 111-base pair (bp) deletion at the 5′ end of exon 5, due to preferential usage of a cryptic splice acceptor site within exon 5, and is transcribed into an mRNA of approximately 4300 nucleotides (NM_033013), which is translated into a protein of 397 amino acids (NP_148934) with a deletion of 37 amino acids in the LBD of variant 1[@bib37], [@bib69]. The 37-amino acid deletion in human PXR3 corresponds to a 41-amino acid deletion in the LBD of the corresponding mouse PXR variant[@bib3]. *PXR2* mRNA originates from the exon 1b of the *hPXR* gene and is transcribed into an mRNA of 2800 nucleotides (NM_022002), which is translated into a protein of 473 amino acids using a ATG start codon in exon 1b (NP_071285) that contains an additional 39 amino acids at the N-terminus, as compared to PXR1[@bib69], [@bib71], [@bib72]. *PXR1* and *PXR2* variants share exon 2 through exon 9 therefore they have identical LBD and DNA-binding domain. Many other PXR variants have been described, including PXR4, also known as short PXR (sPXR), a newly identified 37-kDa short PXR protein containing 322 amino acids that is translated from exon 4 to exon 9 (cDNA AK122990)[@bib72]. The naming of different *PXR* transcript variants and their corresponding abbreviations, though mostly consistent, varies between authors; please refer to the "Abbreviations" section for the naming scheme used throughout this article.

*PXR* splice and transcript variants differ in their effects on target gene transcription[@bib7], [@bib38], [@bib39], [@bib70]. PXR3 lacks the activity of PXR1 in terms of both gene transactivation activity and protein--protein interactions[@bib7], [@bib38], [@bib39], [@bib70], [@bib73], whereas the protein encoded by the *PXR2* mRNA has comparable activity to the main protein, PXR1[@bib7], [@bib38], [@bib70]. Similarly to PXR3, PXR4 has been shown to lack gene transactivational activity, but, in contrast to PXR3, it has an intact LBD[@bib72]. These observations and the lack of exhaustive study into the functions of *PXR* transcript variants highlight the necessity of investigating the functions of these variant proteins and transcripts and their effects on drug metabolism.

The *PXR* transcript variants possess distinct and overlapping functionality. PXR2 was as effective as PXR1 in mediating transcription of *CYP3A7*[@bib7]. Transcription of the *UGT1A* family increased in cells transfected with *PXR1* and *PXR2*, but this was not consistent between *UGT1A* family members: Whereas *UGT1A1*, *UGT1A3*, *UGT1A4*, and *UGT1A6* mRNA were induced to various extents by PXR1 and PXR2 in response to rifampicin treatments, *UGT1A9* mRNA was not induced by rifampicin[@bib7]. PXR3 did not activate *CYP3A7* or *UGT1A* mRNA expression[@bib7], but when *PXR3* was cotransfected with *PXR1*, it displayed a dominant negative effect on PXR1 activation of CYP3A4 induced by rifampicin[@bib39]. Although PXR3 binds to PXR response element, it does not activate the expression of a luciferase reporter construct under the control of the *CYP3A4* promoter (CYP-Luc)[@bib39]. In addition, it binds to corepressors but not coactivators[@bib39]. One study[@bib69] found 9 variants of *PXR1*, 7 of which had deletions in exon 5. PXR3 results from splicing of *PXR1*, whereas PXR2 is generated by an alternate transcription start site and has a first exon distinct from that of *PXR1*. No publications exist that further investigate the *PXR* variants 5--9. Stable transfection of HepG2 and LS180 cells with *PXR1*, but not with *PXR3*, resulted in an increase in *CYP3A4*, *MDR1*, *CYP2B6*, and *UGT1A1* mRNA in both the absence and presence of the PXR agonist rifampicin[@bib38], [@bib39].

The expression profiles of the main *PXR* transcript variants have not been fully elucidated, nor have the implications of the 5′ diversity among the transcripts been fully investigated. There are data available on the organism-wide expression profile for variants 1 and 3, but the expression of other variants has been quantified only in the liver[@bib9], [@bib38], [@bib40], [@bib72]. Quantification of *PXR2* mRNA in a larger sample (*n* = 56) found that *PXR2* represented, on average, approximately 15% of the total *PXR* transcripts in the liver, although this proportion was as high as 60% in some cases[@bib38]. The average mRNA level of *PXR3*, which lacks the transactivation activity of PXR1 on inducing CYP3A4[@bib70] accounts for 7% of the total *PXR* transcripts in the liver[@bib9]. As *PXR* transcript variants 1 to 4 have identical 3′ regions, it would be predicted that similar regulatory mechanisms act on this region in all variants. However, the 5′ region of the *PXR* transcripts differs between *PXR1* and *PXR2*[@bib40], [@bib71], [@bib74], and this 5′ diversity may contribute to differential regulation by transregulatory factors at both the genomic (*i.e*., gene) and post-transcriptional (*i.e*., mRNA) levels[@bib74]. When 5′ rapid amplification of cDNA ends (RACE) sequencing was performed to map the 5′ untranslated region (UTR) of *PXR* transcripts, putative transcription factor binding sites were found upstream of the *PXR2* first exon that were distinct from those in the upstream region of the *PXR1* first exon[@bib74]. As mentioned previously, *PXR1* contains a noncoding exon 1a and uses a CTG start codon located in exon 2[@bib74]. However, *PXR2* contains exon 1b and an ATG start site that results in a protein with an N-terminal addition of 39 amino acids (as compared to variant 1)[@bib74]. The alternating use of exons 1a and 1b results in distinct 5′ regions in *PXR1* and *PXR2*[@bib74]. The characterization of the upstream region of *PXR2* revealed a promoter region 1.5 kb upstream of the major *PXR2* transcript transcription start site that displayed gene transactivation activity when placed upstream from a luciferase gene in a reporter construct[@bib75]. A search of the TRANSFAC transcription factor database (http://www.gene-regulation.com/pub/databases.html) also revealed consensus binding sites for hepatocyte nuclear factor 1 (HNF1), HNF3*β*, and HNF4 in this 1.5-kb region that is required for activating luciferase expression[@bib75]. Further characterization of this promoter region by sequential deletion revealed that a putative HNF1 response element was required for luciferase expression[@bib75]. Additionally, putative TATA boxes and consensus sites for HNF-3*β*, octamer factor 1 (Oct-1), CCAAT/enhancer binding protein *β* (C/EBP*β*), and glucocorticoid receptor (GR), were found upstream of the major transcription start site identified for *PXR1*[@bib74]. In another study, the region upstream of the transcription start site of *PXR1* containing putative transcription factor binding sites displayed promoter activity when placed upstream of a luciferase gene and transfected into HepG2 cells[@bib71]. The authors also mapped the minimal essential region for promoter activity to a 160-bp region upstream of the transcription initiation site, showing that this region also binds to nuclear proteins and that mutations of this region disrupt protein binding and reduce promoter activity. Alternative promoter use would account for the multiple 5′ ends of the transcripts for *PXR1* and *PXR2*[@bib74]. The 5′ regions for *PXR1* and *PXR2* were later extended, and new proximal promoters were identified[@bib40]. Additionally, the exon 3 region with the CpG island also displays promoter activity by luciferase reporter assay[@bib76], suggesting that transcription factors may be able to regulate *PXR4* differently from the other variants, as *PXR4* lacks exon 3.

Interestingly, a 6-bp deletion (^−133^GAGAAG^−128^) spanning the putative HNF1 binding sequence upstream of the *PXR2* transcription start site[@bib74] was reported in a Japanese population[@bib75]. This deletion was associated with a complete loss of promoter activity when conjugated to a luciferase gene and transfected into HepG2 cells. The allele frequency of the deletion variant was 28% in both healthy control subjects and patients with aspirin-induced asthma (AIA), and almost half of the population sampled had this 6-bp deletion, either heterozygously or homozygously. The same 6-bp deletion was further investigated in a Chinese population in healthy controls and in patients with hepatic carcinoma[@bib38]. In this study, the allelic frequency, as determined by analyzing blood samples (*n* = 177), in healthy controls (22%) was significantly different from that in patients with hepatic carcinoma (38%). This research group also reported that *PXR2* mRNA represented an average of 15% of the total *PXR* mRNA expression, with a range from 1% to 60%. The 6-bp deletion reduces the levels of *PXR2* and, thus, of total *PXR* and of *MDR1* and *CYP3A4* mRNA expression[@bib38]. The significantly higher allelic frequency of the 6-bp deletion in patients with hepatic carcinoma might also suggest its correlation with carcinoma formation, possibly as a result of the reduced capacity for detoxification.

4. Relation of *PXR* variant expression and activity in the context of chemotherapeutic response and carcinogenesis {#s0020}
===================================================================================================================

Organism-wide expression profiling studies have revealed an incomplete correlation between the expression of PXR target genes and that of the major transcript variant, PXR1 (434 residues). PXR2 (473 residues), which regulates similar target genes to PXR1, may contribute to this incomplete correlation; however, an organism-wide expression profile for PXR2 has not been attempted[@bib9]. It is possible that the interindividual and tissue variation in target gene expression may be related to the tissue-specific expression of specific *PXR* transcript variants. For example, PXR1 and PXR3 are, in some instances, not expressed in tissues that express CYP3A4, whereas PXR2 may be expressed in those tissues. Similarly, Caco-2 cells only express *PXR1* mRNA, whereas HepG2 cells, human jejunum, and human hepatocytes express *PXR1*, *PXR2*, and *PXR3* mRNA[@bib7]. In addition to tissue-specific expression, the *PXR* transcript variants also display divergent effects on target gene transcription. PXR3 binds to the PXR response element but fails to activate the expression of PXR target genes in response to PXR ligands[@bib39]. Instead, it functions as a dominant negative interfering with PXR1[@bib39]. PXR1 and PXR2, but not PXR3, induce *CYP3A7*, *UGT1A1*, *UGT1A3*, and *UGT1A4* mRNA in HepG2 and Caco-2 cells in response to rifampicin[@bib7]. These data suggested that both PXR1 and PXR2, although they may be differentially expressed, contribute to the overall PXR activity[@bib7]. Conversely, PXR3 and PXR4 lack transcriptional activity in inducing target gene expression[@bib39], [@bib72]. Thus, the relative expression levels of the *PXR* transcript variants may directly affect chemotherapeutic metabolism.

A recent report describes the inverse correlation between the expression level of PXR4 and the methylation status of a CpG island upstream of exon 3, as well as the effect of overexpressed PXR4 protein in reducing cell proliferation markers[@bib72]. The CpG island was reported to be methylated in various cell lines and normal colon tissue, and the methylation status of this region did not affect *PXR1* mRNA expression[@bib77]. PXR4 contains 322 amino acids, is homologous to the LBD of PXR1 and PXR2, retains ligand and coregulator binding capacity, and is detectable in the nucleus, but it lacks target gene transactivation activity[@bib72]. These investigators also found *PXR4* to represent approximately 10% of the total *PXR* mRNA expressed in human livers. Overexpression of PXR4 in HepG2 cells decreased cellular proliferation and rifampicin-induced expression of CYP3A4 and FGF19[@bib72]. The authors postulated that PXR4 was a tumor suppressor functioning as a dominant negative against PXR1. Although no significant difference in expression of *PXR4* mRNA was observed in normal tissue and hepatocellular carcinoma or adenoma, the authors did observe differences in expression of *PXR4* mRNA among certain tumor subtypes. For example, *PXR4* mRNA was decreased in inflammatory hepatocellular adenomas compared to normal livers or noninflammatory subtypes. Interestingly, higher levels of *PXR4* mRNA expression were associated with favorable prognostic indicators and greater disease-free survival, whereas lower levels of expression in subtypes of hepatocellular carcinoma were associated with poor prognoses. The authors also observed decreased expression of PXR4 in the inflammatory subtype of hepatocellular adenoma that is believed to progress to hepatocellular carcinoma as a result of inflammatory activation *via* the JAK/STAT pathway. These observations suggest that the suppressive effect of PXR4 on PXR target genes may also extend to interactions with the NF-*κ*B pathway, a pathway known to interact with PXR[@bib14], [@bib72], [@bib78], [@bib79]. PXR4 may thus serve as a prognostic marker in hepatic carcinoma, as well as playing a role in the malignant transformation of hepatic carcinomas.

The *PXR* variants may also display differential behavior in protein--protein interactions. It has been reported that p53 interacts with PXR1 and represses PXR-mediated transactivation of the *CYP3A4* promoter. However, PXR3 does not interact with p53[@bib73]. The p53 protein, mutated in many cancers, is a tumor suppressor that leads to cell cycle arrest, DNA repair, and apoptosis when activated by a wide array of genotoxic stresses[@bib80], [@bib81]. Interestingly, while both the wild-type and mutated forms of p53 interact with PXR, only the wild-type form inhibits PXR activity[@bib73]. Therefore, cell populations with a mutant p53 protein will have higher levels of PXR transcriptional activity and drug-metabolizing enzymes, such as CYP3A4, possibly rendering these populations less responsive to chemotherapeutic agents that are metabolized by CYP3A4. Whether other PXR protein variants interact with p53 has not been investigated.

As discussed earlier, the differential regulation of PXR1 and PXR2 resulting from their different 5′ UTRs may contribute to the differential expression of the variants and the levels of total PXR and its target genes, which might be associated with differential risk of carcinoma formation and the response of cancer to chemotherapeutic agents.

Methylation of the *PXR* promoter was first reported in detail in neuroblastoma[@bib76]. Neuroblastoma is the most common solid tumor in children, with advanced stages having an incidence of mortality greater than 60%[@bib82], [@bib83]. Normal adrenal tissue, the tissue of origin of neuroblastoma, expresses *PXR1* mRNA exclusively[@bib76]. Hypermethylation in CpG-rich exons and promoter regions has been observed in many cancers and can lead to the transcriptional inactivation of tumor suppressors[@bib84]. *PXR* mRNA expression was analyzed across a panel of 19 neuroblastoma cell lines, and no PXR was detected in 14 of the cell lines[@bib76]. By using bacterial artificial chromosome array-based methylated CpG island amplification (BAMCA), the promoter of *PXR* was found to be methylated in several neuroblastoma cell lines and primary tumors[@bib76]. Specifically, *PXR* mRNA was expressed in the low-grade tumors but not in the advanced neuroblastoma cell lines analyzed. However, *PXR* mRNA expression increased in the advanced neuroblastoma cell lines after they were treated with 5-aza-Cyd, an inhibitor of DNA methyltransferase[@bib76]. The authors performed bisulfite sequencing in the exon 1a region and in a region of exon 3. Methylation of the exon 3 region was more frequently detected in advanced tumors, tumors from patients with a poor prognosis, and tumors from patients who were more than 1 year of age. The methylation status of exon 1a did not correlate with *PXR* mRNA expression. However, hypermethylation of the exon 3 region was detected in cell lines lacking *PXR* mRNA expression (IMR32 and SH-SY5Y), whereas hypomethylation, as well as *PXR* mRNA expression, was detected in a normal lymphoblast cell line and two neuroblastoma cell lines (SK-N-AS and SK-N-KP). The exon 3 region with the CpG island exhibited promoter activity. Additionally, there was no detectable difference in the methylation status of the exon 1a region among these cell lines. *PXR1* and *PXR2* mRNA were expressed in cell lines in which the *PXR* promoter is unmethylated, but not in cell lines with methylated *PXR* promoters. In cell lines with methylated *PXR* promoter, the expression of *PXR1* mRNA, but not of *PXR2* mRNA, was restored by the treatment with 5-aza-Cyd. *PXR2* was detected in the hypomethylated (SJ-N-KP and SK-N-AS) cell lines and not in the hypermethylated ones (SJ-N-GC and SMS-KAN), whereas *PXR3* mRNA was not expressed in any of the cell lines, regardless of their methylation status or whether they were treated with 5-aza-Cyd. Consequently, the methylation status of separate regions of the *PXR* gene differentially regulates the expression of specific *PXR* variants. In this study, the ectopic overexpression of PXR decreased cell proliferation, suggesting that PXR functions as a tumor suppressor[@bib76]. However, whether this finding is specific to neuroblastoma cell lines is unclear.

In colon cancer cell lines, *PXR* promoter methylation was associated with *PXR* mRNA and *CYP3A4* mRNA expression levels[@bib77]. Moreover, the *PXR* promoter was less methylated and *PXR* and *CYP3A4* mRNA expression levels were correspondingly higher in cancerous colon tissues than in adjacent normal tissues. In a xenograft model of colon cancer, PXR activation correlates with the growth of both human colon tumor cell lines and primary human colon cancer tissue. PXR potentially functions as an oncogene[@bib85]. In colon cancer cell lines (LS180, LoVo, Caco-2, HCT116, HT29, and SW48), *PXR* and *CYP3A4* mRNA levels were associated with hypermethylation of a CpG-rich sequence in the promoter of *PXR* and were increased after treatment with 5-aza-dC[@bib77]. The cell lines that express high levels of PXR1 and low levels of PXR2 and PXR3 have mostly methylated CpG-rich sequences in exon 1b and in the intron of the 3′ end of exon 1b. However, a mostly unmethylated CpG-rich sequence exists in exon 1a and in the intron of the immediate 3′ end of exon 1a in the cell lines with higher expression of PXR (LS180 and LoVo)[@bib77]. Thus, it would seem that the mRNA expression of different *PXR* variants could be differentially regulated by methylation. It would be expected that methylation of the CpG-rich sequences in and around exon 1a might specifically affect the expression of *PXR1* mRNA and *PXR3* mRNA, whereas the methylation status of and near exon 1b would affect the expression patterns of *PXR2* mRNA. In colon cancer cells excised from colonic tissue samples, the CpG island within the exon 3 region is the most methylated region of the *PXR* gene, whereas the CpG-rich sequence around exon 1a is the most unmethylated region[@bib77]. The CpG-rich sequence around exon 1b is methylated in these colon cancer cells, and this may correlate with low *PXR2* mRNA expression. Additionally, the methylation of the CpG island within exon 3 seen in cell lines[@bib77] may be associated with low expression of PXR4 and, subsequently, with higher expression observed after treatment with a demethylating agent[@bib72]. Therefore, determination of the protumor effect of PXR in colon cancer may involve a complex series of events that requires a specific relative expression pattern of multiple transcript variants. Additional analysis of the methylation of *PXR* variants in different tumor types is warranted to further establish the correlation between methylation and expression of PXR and tumor development, as well as tumor response to chemotherapeutic agents.

5. Conclusions {#s0025}
==============

It is clinically and scientifically important to elucidate the functions of the *PXR* variants in order to predict the outcome of ligand activation of PXR and the role of PXR in various model systems. PXR is activated by structurally and functionally diverse ligands that are associated with and prescribed in a multitude of disease states. A greater understanding of the roles of the *hPXR* transcript variants would greatly contribute to predicting therapeutic failure of cotherapies arising from xenosensor-mediated decreases in drug bioavailability or increases in toxicity. For example, high overall PXR expression and low PXR3 (which functions in a dominant negative manner) expression may result in decreased drug bioavailability whereas high overall PXR expression and high PXR3 expression (compared to transcriptionally active variants) would be expected to result in increased drug bioavailability. PXR1 plays a well-described role in the detoxifying drug metabolism pathways of cancer therapeutics and can cause treatment failure at high levels of expression. PXR2 has similar effect on target gene transactivation but has not been fully characterized in terms of coregulator recruitment, ligand response, protein--protein interactions, or organism-wide tissue expression. PXR3 has been reported to recruit corepressors but does not similarly participate in the protein--protein interactions associated with PXR1 or transactivate PXR target genes. However, it is unknown whether the dominant negative effect of PXR3 plays a significant pathophysiologic or physiologic role. PXR4 has been reported to compete with PXR1 in binding to ligand and coactivators to exert a dominant negative effect, as has PXR3 with respect to PXR1 transactivational activity. Several of these transcripts have been implicated in cancer pathogenesis, with PXR1 expression being a negative prognostic factor in some but not all cancers because of its role in drug metabolism and transport. There have been many contradictory reports concerning the effects of PXR1 on cellular proliferation and apoptosis; these effects may be more clearly defined by investigating the roles of the variants in these various model systems. *PXR* polymorphisms, the use of alternate promoters, and splicing variations have not been fully elucidated in terms of expression across disease states and transactivation profiles of target genes. Future studies investigating the role of PXR on drug metabolism would be remiss not to evaluate multiple transcript variants and the resultant proteins.
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###### 

Examples of hPXR agonists.

Table 1

  Compound                                         Description (indication, drug class, etc.)                               Reference
  ------------------------------------------------ ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------
  12-Ketolithocholic acid                          Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  3-Keto-7*α*,12*α*-dihydroxy-5*α*-cholanic acid   Bile salt found in sea lamprey                                           Krasowski et al. (2005)[@bib24]
  5*α*-Cyprinol 27-sulfate                         Bile salt found in zebrafish                                             Krasowski et al. (2005)[@bib24]
  5*β*-Pregnane-3,20-dione                         Steroid hormone                                                          Jones et al. (2000)[@bib25]
  5*β*-Scymnol 27-sulfate                          Bile salt found in cartilaginous fish                                    Krasowski et al. (2005)[@bib24]
  7,12-Diketolithocholic acid                      Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  7-Ketodeoxycholic acid                           Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  7-Ketolithocholic acid                           Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Carbemazepine                                    Epilepsy                                                                 Luo et al. (2002)[@bib26]
  Cholic acid                                      Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Clotrimazole                                     Anti-fungal                                                              Xie et al. (2000)[@bib27]; Luo et al. (2002)[@bib26]; Xie et al. (2003)[@bib28]; Jones et al. (2000)[@bib25]
  Corticosterone                                   Glucocorticoid                                                           Jones et al. (2000)[@bib25]
  Cyproterone acetate                              Antineoplastic (prostate); androgen disorders, steroidal anti-androgen   Jones et al. (2000)[@bib25]
  Deoxycholic acid                                 Bile salt found in rabbit                                                Krasowski et al. (2005)[@bib24]
  Dexamethasone                                    Glucocorticoid                                                           Xie et al. (2000)[@bib27]; Luo et al. (2002)[@bib26]
  Dexamethasone-*t*-butyl acetate                  Glucocorticoid                                                           Synold et al. (2001)[@bib29]; Luo et al. (2002)[@bib26]
  Estradiol                                        Steroid hormone                                                          Luo et al. (2002)[@bib26]
  Glycolithocholic acid                            Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Glycolithocholic acid 3-sulfate                  Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Hyodeoxycholic acid                              Bile salt found in many mammals                                          Krasowski et al. (2005)[@bib24]
  Hyperforin                                       St. John׳s Wort; herbal supplement commonly used for depression          Luo et al. (2002)[@bib26]
  Lithocholic acid                                 Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Lithocholic acid 3-sulfate                       Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Lithocholic acid acetate                         Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Lithocholic acid acetate methyl ester            Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Mifepristone (RU486)                             Pregnancy termination, steroidal antiprogesterone                        Xie et al. (2000)[@bib27]; Jones et al. (2000)[@bib25]
  Nonylphenol                                      Anthropogenic environmental estrogen                                     Mota et al. (2011)[@bib30]
  Paclitaxel (Taxol)                               Anti-neoplastic                                                          Synold et al. (2001)[@bib29]; Luo et al. (2002)[@bib26]
  Petromyzonol 24-sulfate                          Bile salt found in sea lamprey                                           Krasowski et al. (2005)[@bib24]
  Phenobarbital                                    Epilepsy                                                                 Jones et al. (2000)[@bib25]; Luo et al., (2002)[@bib26]
  Pheytoin                                         Seizure disorders                                                        Luo et al. (2002)[@bib26]
  Piperine                                         Component of the spice, black pepper                                     Wang et al. (2013)[@bib31]
  Pregnenolone                                     Steroid hormone                                                          Jones et al. (2000)[@bib25]
  Progesterone                                     Steroid hormone                                                          Jones et al. (2000)[@bib25]
  Rifampicin                                       A component of the first line anti-tuberculosis therapy                  Jones et al. (2000)[@bib25]; Synold et al. (2001)[@bib29]; Xie et al. (2000)[@bib27]; Xie et al. (2003)[@bib28]; Luo et al. (2002)[@bib26]
  Ritonavir                                        HIV, protease inhibitor                                                  Luo et al. (2002)[@bib26]
  Spironolactone                                   Diuretic, steroidal anti-mineralocorticoid                               Jones et al. (2000)[@bib25]
  SR12813                                          Dyslipidemia, HMG-CoA inhibitor                                          Jones et al. (2000)[@bib25]; Synold et al. (2001)[@bib29]
  Sulfadimidine                                    Antibiotic, sulfonamide                                                  Luo et al. (2002)[@bib26]
  Sulfinpyrazone                                   Gout                                                                     Luo et al. (2002)[@bib26]
  Taurochenodeoxycholic acid                       Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Taurohyodeoxycholic acid                         Bile salt found in many mammals                                          Krasowski et al. (2005)[@bib24]
  Taurolithocholic acid                            Bile salt found in humans                                                Krasowski et al. (2005)[@bib24]
  Trans-nonachlor (Chlordane)                      Pesticide                                                                Jones et al. (2000)[@bib25]
  Troglitazone                                     Diabetes (withdrawn), thiazolidinedione                                  Jones et al. (2000)[@bib25]
  Troleandomycin                                   Antibiotic, macrolide                                                    Luo et al. (2002)[@bib26]
  *α*-Muricholic acid                              Bile salt found in rat                                                   Krasowski et al. (2005)[@bib24]
